Literature DB >> 11207581

Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization.

K E Beauregard1, R J Collier, J A Swanson.   

Abstract

Immunofluorescence and other methods have been used to probe the self-assembly and internalization of the binary toxin, anthrax lethal toxin (LeTx), in primary murine macrophages. Proteolytic activation of protective antigen (PA; 83 kDa, the B moiety of the toxin) by furin was the rate-limiting step in internalization of LeTx and promoted clearance of PA from the cell surface. A furin-resistant form of PA remained at the cell surface for at least 90 min. Oligomerization of receptor-bound PA63, the 63 kDa active fragment of PA, was manifested by its conversion to a pronase-resistant state, characteristic of the heptameric prepore form in solution. That oligomerization of PA63 triggers toxin internalization is supported by the observation that PA20, the complementary 20 kDa fragment of PA, inhibited clearance of nicked PA. The PA63 prepore, with or without lethal factor (LF), cleared slowly from the cell surface. These studies show that proteolytic cleavage of PA, in addition to permitting oligomerization and LF binding, also promotes internalization of the protein. The relatively long period of activation and internalization of PA at the cell surface may reflect adaptation of this binary toxin that maximizes self-assembly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11207581     DOI: 10.1046/j.1462-5822.2000.00052.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  44 in total

1.  The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.

Authors:  Jeremy Mogridge; Kristina Cunningham; D Borden Lacy; Michael Mourez; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

3.  Membrane insertion by anthrax protective antigen in cultured cells.

Authors:  Maen Qa'dan; Kenneth A Christensen; Lei Zhang; Thomas M Roberts; R John Collier
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin.

Authors:  Wei Wang; Chandrika Mulakala; Sabrina C Ward; Grace Jung; Hai Luong; Duy Pham; Alan J Waring; Yiannis Kaznessis; Wuyuan Lu; Kenneth A Bradley; Robert I Lehrer
Journal:  J Biol Chem       Date:  2006-06-21       Impact factor: 5.157

5.  Onset of anthrax toxin pore formation.

Authors:  Mu Gao; Klaus Schulten
Journal:  Biophys J       Date:  2006-02-10       Impact factor: 4.033

6.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

Review 7.  Processing of peptide and hormone precursors at the dibasic cleavage sites.

Authors:  Mohamed Rholam; Christine Fahy
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

8.  The cytoplasmic domain of anthrax toxin receptor 1 affects binding of the protective antigen.

Authors:  Mandy Y Go; Edith M C Chow; Jeremy Mogridge
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

9.  Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake.

Authors:  Laurence Abrami; Béatrice Kunz; F Gisou van der Goot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.